BSX icon

Boston Scientific

102.95 USD
+0.00
0.00%
At close May 14, 4:00 PM EDT
After hours
102.95
+0.00
0.00%
1 day
0.00%
5 days
-2.07%
1 month
9.21%
3 months
-2.98%
6 months
17.54%
Year to date
15.18%
1 year
40.09%
5 years
190.00%
10 years
474.82%
 

About: Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Employees: 53,000

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

154% more first-time investments, than exits

New positions opened: 211 | Existing positions closed: 83

25% more repeat investments, than reductions

Existing positions increased: 603 | Existing positions reduced: 482

11% more funds holding in top 10

Funds holding in top 10: 35 [Q3] → 39 (+4) [Q4]

10% more capital invested

Capital invested by funds: $109B [Q3] → $120B (+$10.8B) [Q4]

8% more funds holding

Funds holding: 1,372 [Q3] → 1,479 (+107) [Q4]

2.23% more ownership

Funds ownership: 88.28% [Q3] → 90.51% (+2.23%) [Q4]

13% less call options, than puts

Call options by funds: $797M | Put options by funds: $912M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$112
9%
upside
Avg. target
$118
15%
upside
High target
$125
21%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
Barclays
Matt Miksic
56% 1-year accuracy
22 / 39 met price target
21%upside
$125
Overweight
Maintained
25 Apr 2025
Needham
Mike Matson
42% 1-year accuracy
48 / 114 met price target
12%upside
$115
Buy
Maintained
24 Apr 2025
RBC Capital
Shagun Singh
48% 1-year accuracy
33 / 69 met price target
17%upside
$120
Outperform
Maintained
24 Apr 2025
Truist Securities
Richard Newitter
56% 1-year accuracy
28 / 50 met price target
14%upside
$117
Buy
Maintained
24 Apr 2025
Evercore ISI Group
Vijay Kumar
35% 1-year accuracy
15 / 43 met price target
9%upside
$112
Outperform
Maintained
24 Apr 2025

Financial journalist opinion

Based on 36 articles about BSX published over the past 30 days

Positive
Zacks Investment Research
15 hours ago
Is it Worth Retaining Boston Scientific Stock in Your Portfolio Now?
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and strategic acquisitions.
Is it Worth Retaining Boston Scientific Stock in Your Portfolio Now?
Neutral
Seeking Alpha
1 day ago
Boston Scientific Corporation (BSX) Bank of America's 2025 Health Care Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX ) Bank of America's 2025 Health Care Conference May 13, 2025 11:00 AM ET Company Participants Daniel Brennan - EVP & CFO Joe Fitzgerald - EVP & Group President, Cardiology Conference Call Participants Travis Steed - Bank of America Travis Steed All right. Good morning, everybody.
Boston Scientific Corporation (BSX) Bank of America's 2025 Health Care Conference (Transcript)
Positive
Zacks Investment Research
2 days ago
PAHC or BSX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
PAHC or BSX: Which Is the Better Value Stock Right Now?
Positive
Zacks Investment Research
6 days ago
Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock
Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock
Neutral
Investors Business Daily
1 week ago
Boston Scientific Stock Flirts With A Buy Point, Once Again
Boston Scientific stock is wavering around the buy point of a double-bottom base. The company recently raised its 2025 earnings outlook.
Boston Scientific Stock Flirts With A Buy Point, Once Again
Negative
Zacks Investment Research
1 week ago
MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.
MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know
Positive
Zacks Investment Research
1 week ago
These 3 Stocks Soared Following Strong Quarterly Results
The 2025 Q1 earnings cycle is in full swing. And these three companies posted results that had investors pleased.
These 3 Stocks Soared Following Strong Quarterly Results
Neutral
PRNewsWire
1 week ago
Boston Scientific announces upcoming investor conference schedule
MARLBOROUGH, Mass. , May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.
Boston Scientific announces upcoming investor conference schedule
Positive
Zacks Investment Research
2 weeks ago
Earnings Season: 3 Companies Raising Guidance
Raising guidance? In this uncertainty?
Earnings Season: 3 Companies Raising Guidance
Positive
Seeking Alpha
2 weeks ago
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Charts implemented using Lightweight Charts™